Floatz logo

Romidepsin

Peripheral T-Cell Lymphoma, Not Otherwise Specified

University of VirginiaSmall moleculePhase 3Active
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
95/ 100

Competitive context

127 Active assets in the Peripheral T-Cell Lymphoma, Not Otherwise Specified cohort.

Asset / SponsorPhaseRating
Pralatrexate
Peking University People's Hospital
Phase 4BBB
Adriamycin
BeBetter Med Inc
Phase 4BBB
Prednisone
Tarapeutics Science Inc.
Phase 4BBB
Cyclophosphamide
Tarapeutics Science Inc.
Phase 4BBB
(+)-Vincristine
BeBetter Med Inc
Phase 4BBB

View all 50 →

Same molecule, other indications

Romidepsin is also rated in:

follicular lymphomaDormant
BBB
Indicative · Phase 2
73 / 100
View asset →
Burkitt lymphomaActive
BBB
Indicative · Phase 2
73 / 100
View asset →
chronic myeloid leukemiaActive
BBB
Indicative · Phase 2
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →